Lung Cancer Screening: Who Should Get Tested and How
Written by: North Editorial Staff, reviewed by Laura Morrissey, RN, BSN · Last reviewed: February 2026 · Next review due: February 2027
Key Takeaways
Low-dose CT screening can reduce lung cancer deaths by 20% in high-risk individuals, according to the National Lung Screening Trial
USPSTF guidelines recommend screening for adults aged 50–80 with a 20+ pack-year smoking history who currently smoke or quit within the past 15 years
Early detection dramatically improves survival rates: approximately 65% five-year survival for localized lung cancer versus 9% for distant-stage cancer
Most nodules detected during screening are benign, but may require follow-up imaging, which can cause anxiety and additional costs
LDCT screening is covered by Medicare and most private insurance when patients meet eligibility criteria
Clinical trials offer opportunities for access to advanced screening technologies and personalized risk assessment
Introduction
According to the U.S. Preventive Services Task Force (USPSTF), lung cancer screening using low-dose computed tomography (LDCT) can reduce lung cancer mortality by 20% among high-risk individuals. If you have a significant smoking history, screening may be one of the most important steps you can take to protect your health and catch lung cancer at an early, more treatable stage.
Lung cancer remains the leading cause of cancer death in both men and women in the United States. Yet when caught early, survival rates improve dramatically. This guide will help you understand what lung cancer screening involves, whether you qualify for screening, and what happens next if abnormalities are detected.
The decision to pursue lung cancer screening is deeply personal. Understanding the facts empowers you to have meaningful conversations with your healthcare provider about whether screening is right for your situation.
What Is Lung Cancer Screening?
Lung cancer screening uses a low-dose computed tomography (LDCT) scan, also called a low-dose CT scan, to look for early signs of lung cancer in high-risk individuals. Unlike a standard CT scan, which uses higher radiation doses, an LDCT scan delivers minimal radiation exposure while providing clear images of your lungs and airways.
How Low-Dose CT Scanning Works
During an LDCT screening, you'll lie on a narrow table that slides into a donut-shaped machine. The scanner rotates around your chest, taking detailed cross-sectional images of your lungs. The entire scan typically takes about 10 minutes. You'll be asked to hold your breath for a few seconds while the images are captured, but the procedure is painless and non-invasive.
No contrast dye is needed for a screening LDCT scan, which means no needles or injections are required. The radiation exposure is significantly lower than a standard chest CT — roughly equivalent to about 1–2 chest X-rays, making it a low-risk procedure.
Why LDCT Is Effective for Early Detection
LDCT can detect lung nodules (small growths) that are often too small to see on conventional X-rays. Many of these nodules are benign (non-cancerous), but the ability to identify small abnormalities early means that if lung cancer is present, it's often caught before it has spread to other parts of the body. This dramatically improves treatment options and outcomes.
The National Lung Screening Trial (NLST), a landmark study that compared LDCT screening to chest X-rays in over 50,000 high-risk smokers, demonstrated that LDCT screening reduced lung cancer deaths by 20% compared to standard chest X-ray screening. This evidence forms the foundation of current screening recommendations.
Who Should Get Screened for Lung Cancer
Not everyone needs lung cancer screening, but if you fall into a high-risk category, talking to your doctor about screening is an important conversation to have.
USPSTF Screening Guidelines (2021)
The U.S. Preventive Services Task Force (USPSTF) recommends annual LDCT screening for adults aged 50–80 years who meet the following criteria:
20 or more pack-year smoking history (a pack-year is defined as smoking one pack per day for one year; for example, smoking half a pack per day for 40 years equals 20 pack-years)
Currently smoke or quit smoking within the past 15 years
According to the USPSTF, these guidelines represent the population most likely to benefit from screening based on evidence from large prospective trials.
Expanded Screening Criteria
While the USPSTF criteria provide the foundation for screening recommendations, other organizations such as the American Cancer Society (ACS) and the National Comprehensive Cancer Network (NCCN) have proposed slightly different guidelines that may include some individuals outside these parameters. For example:
People with a history of lung disease (such as COPD or interstitial lung fibrosis)
Those with a significant family history of lung cancer
Individuals with exposure to secondhand smoke, radon, or occupational carcinogens
Those aged 40–49 with very high-risk factors
If you're not certain whether you meet screening criteria, or if your smoking history falls outside the typical range, speak with your primary care provider or a pulmonologist about your individual risk factors.
Why Screening Eligibility Matters
Screening is most beneficial for individuals at high risk. This is because the likelihood of finding cancer must outweigh the potential risks and burdens of screening and follow-up procedures. Your healthcare provider can assess your personal risk profile and recommend whether screening is appropriate for you.
Benefits of Early Detection
Early detection of lung cancer can be life-changing. When lung cancer is found at an early stage, before it has spread, treatment options are broader and survival rates are significantly better.
Survival Rates by Stage
According to the American Cancer Society, the five-year survival rate for localized lung cancer (cancer confined to the lungs) is approximately 65%. In contrast, when lung cancer has spread to distant organs at the time of diagnosis, the five-year survival rate drops to approximately 9%.
These statistics underscore a critical truth: finding lung cancer early, when it's localized and potentially curable, can make an enormous difference in your outcome.
The NLST Trial Evidence
The National Lung Screening Trial followed over 50,000 high-risk smokers over several years. Participants were randomly assigned to receive either annual LDCT screening or standard chest X-ray screening. The study found that:
LDCT screening reduced lung cancer deaths by 20% compared to chest X-ray screening
Annual screening with LDCT was more effective at detecting early-stage cancers
Early detection allowed more patients to be candidates for surgery and other potentially curative treatments
This 20% reduction in mortality represents thousands of lives saved and forms the evidence base for current screening recommendations.
More Treatment Options at Early Stages
Early-stage lung cancers may be treated with surgery alone, which offers the best chance for cure. As cancer progresses and spreads, treatment often becomes more complex, involving combinations of surgery, chemotherapy, radiation, targeted therapy, or immunotherapy. The more limited the cancer, the simpler and often more effective the treatment approach.
Additionally, early detection may make you eligible for clinical trials testing cutting-edge therapies and screening technologies, which can provide access to innovative treatment options.
What to Expect During a Screening
Understanding what happens during a lung cancer screening appointment can help you feel more prepared and relaxed. You’ll receive detailed instructions specific to the procedure and to the clinic administering the test, but here’s a generalized idea of what to expect at each stage of the process.
Before Your Appointment
No special preparation is required for an LDCT screening. You can eat and drink normally, take your regular medications, and go about your day as usual. However, if you have any metal implants (such as pacemakers or metallic joint replacements), inform your healthcare facility in advance, as this may affect imaging.
Wear comfortable, loose-fitting clothing without metal buttons, zippers, or metallic jewelry, which you'll need to remove before the scan.
During the Screening
When you arrive, you'll check in and complete any necessary paperwork. A technologist will explain the procedure and answer any questions. You'll be asked to remove any metal objects and change into a hospital gown if needed.
In the scanning room, you'll lie on your back on a narrow table that slides into the CT scanner. The technologist will position your arms above your head. You'll be asked to hold your breath for about 10–15 seconds while the scanner takes images. The procedure is painless, and the technologist can communicate with you throughout.
The entire appointment, including check-in and scanning, typically takes 30–45 minutes.
After Your Screening
You can resume your normal activities immediately after the screening. There are no side effects from the scan itself.
Your images will be reviewed by a radiologist, a physician who specializes in interpreting medical images. You should expect to receive your results within 1–2 weeks.
Understanding Your Results: The Lung-RADS Scoring System
Radiologists use a standardized system called Lung-RADS (Lung Imaging Reporting and Data System) to categorize findings and guide next steps:
Lung-RADS 1 (Negative): No nodules detected or only benign findings. Continue routine screening annually.
Lung-RADS 2 (Benign): Small nodules that are almost certainly benign. Continue routine screening in 12 months.
Lung-RADS 3 (Probably Benign): Nodules with features suggesting a low probability of malignancy. Follow-up imaging in 3–4 months.
Lung-RADS 4 (Suspicious): Nodules with features that raise concern for malignancy. Further evaluation recommended, which may include additional imaging or biopsy.
Lung-RADS 5 (Malignant): Strong suspicion for malignancy. Urgent evaluation and likely biopsy or other diagnostic procedures.
What If Something Is Found?
If a nodule or abnormality is detected, your doctor will discuss the findings with you and recommend appropriate next steps. In many cases, this means follow-up imaging in a few months to monitor the nodule and see if it changes. Some findings may require additional imaging with a contrast-enhanced CT scan, PET scan, or lung MRI for better characterization.
If there's concern that a nodule might be cancerous, a biopsy may be recommended. This involves obtaining a tissue sample for pathological examination. Biopsies can be performed in several ways:
Bronchoscopy: A thin tube with a camera is passed through your airways to reach the nodule
CT-guided needle biopsy: A thin needle is guided to the nodule using CT imaging
Surgical biopsy: In some cases, surgical removal of the nodule is both diagnostic and therapeutic
Your pulmonologist or thoracic surgeon will discuss which approach is best for your situation.
Risks and Limitations of Screening
While lung cancer screening with LDCT offers significant benefits, it's important to understand potential drawbacks and limitations.
False Positives and Nodule Follow-up
One of the most common results of lung cancer screening is the discovery of a small nodule that is eventually determined to be benign. According to the 2021 USPSTF recommendation statement, approximately 10–25% of screening LDCT exams identify nodules that require follow-up imaging or monitoring.
Most of these nodules are not cancer, but the uncertainty can create anxiety while waiting for follow-up scans. The repeated imaging and monitoring can be stressful, time-consuming, and costly, even when no cancer is ultimately found. This is known as a "false positive" — a finding that initially raises concern but is later determined to be benign.
Overdiagnosis
Overdiagnosis occurs when screening detects a cancer that would never have caused harm or death if left undetected. With lung cancer screening, this is relatively rare but possible. Some very slow-growing lung cancers detected by screening might never progress or cause symptoms in your lifetime. However, once a cancer is diagnosed, treatment is typically recommended, which may mean undergoing surgery or other therapies for a condition that might not have threatened your life.
The difficulty lies in predicting which cancers are truly dangerous and which are not — a limitation of our current diagnostic tools. Your doctor can help weigh the risks and benefits based on your specific situation.
Radiation Exposure
Although LDCT uses significantly lower radiation doses than standard CT scans, some radiation exposure does occur. The USPSTF notes that the estimated effective dose from a single LDCT scan is approximately 1–2 millisieverts (mSv) — comparable to the natural background radiation you receive over 1–2 years.
For most high-risk individuals, the benefit of early cancer detection outweighs the small additional radiation risk. However, if you're pregnant or have concerns about cumulative radiation exposure, discuss these with your healthcare provider before screening.
Screening-Related Anxiety
Learning that a nodule has been found, even if it's likely benign, can cause significant anxiety and stress. The uncertainty during the follow-up period can affect your quality of life and mental health. It's important to recognize this emotional burden as a real potential consequence of screening and to seek support if you're struggling with anxiety.
Incidental Findings
LDCT scans may detect abnormalities unrelated to lung cancer, such as heart disease, thyroid nodules, or adrenal masses. While some of these findings may be important, others may lead to further testing and potential overtreatment of conditions that would never have caused problems.
Who May Not Benefit From Screening
Screening is not recommended for people with a life expectancy of less than 10 years, as the benefits of early cancer detection are unlikely to improve overall survival. If you have serious health conditions that would prevent you from undergoing treatment for lung cancer if it were found, screening may not be appropriate for you.
Insurance Coverage for Lung Cancer Screening
Understanding insurance coverage can help you plan for screening and avoid unexpected costs.
Medicare Coverage
According to the Centers for Medicare and Medicaid Services (CMS), Medicare covers annual LDCT screening for eligible beneficiaries at no cost to the patient (no copay, coinsurance, or deductible). To be eligible, you must:
Be between 50–77 years old (note: Medicare's age range differs slightly from the USPSTF's 50–80 recommendation)
Have at least a 20 pack-year smoking history
Currently smoke or have quit within the past 15 years
Be asymptomatic (have no signs or symptoms of lung cancer)
Receive counseling about the benefits and risks of screening
Medicare also covers shared decision-making visits, where you can discuss screening with your healthcare provider.
Private Insurance
The Affordable Care Act (ACA) requires that private health insurance plans cover screening services that receive an A or B rating from the USPSTF, without cost-sharing (no copayment, coinsurance, or deductible). Since LDCT lung cancer screening received a B rating from the USPSTF in 2021, most private insurance plans are required to cover it.
However, coverage policies may vary, so it's wise to:
Contact your insurance company before scheduling a screening
Ask whether prior authorization is required
Verify that the imaging facility is in-network
Confirm whether related counseling visits are also covered
How to Check Your Eligibility
Contact your insurance company with your policy number and ask specifically about coverage for LDCT lung cancer screening
Talk with your primary care provider, who can help assess your eligibility based on USPSTF or other guidelines
Visit your insurer's website for information about preventive care coverage
Contact the radiology facility where you plan to have screening, as their billing department can often verify coverage details
If you're uninsured or underinsured, ask your healthcare provider about community health centers or screening programs that may offer reduced-cost or free screening.
Screening and Clinical Trials
Lung cancer screening is evolving rapidly, with numerous clinical trials exploring new approaches and technologies to improve early detection and outcomes.
Types of Lung Cancer Screening Trials
Prevention Trials investigate ways to reduce lung cancer risk in high-risk individuals. These may involve new medications, supplements, or lifestyle interventions designed to prevent cancer development before screening is needed.
Early Detection and Imaging Technology Trials test new or improved screening methods, such as:
Advanced imaging algorithms that use artificial intelligence to improve nodule detection and characterization
Liquid biomarker tests (blood tests) that can detect cancer-related changes before imaging abnormalities appear
Novel PET imaging techniques for better nodule characterization
Hybrid imaging approaches combining multiple technologies
Screening Strategy Trials compare different screening schedules, risk stratification models, or follow-up protocols to determine the most effective approach.
Why Participate in a Screening Trial?
Participating in a screening clinical trial offers several potential advantages:
Access to cutting-edge screening technology or diagnostic methods
More frequent or intensive monitoring that may detect cancer at an earlier stage
Potential cost savings or free screening
Contribution to medical knowledge that may benefit others
Closer interaction with specialists and research teams
If you're eligible for screening and interested in participating in a trial, ask your healthcare provider about opportunities in your area, or visit the North clinical trials finder to search for lung cancer screening trials near you.
Frequently Asked Questions
Is lung cancer screening painful?
No, lung cancer screening with low-dose CT is completely painless. You'll lie on a table while the scanner takes images, and you may be asked to hold your breath briefly. The entire procedure takes about 10 minutes and causes no discomfort.
What's the difference between screening and diagnostic imaging?
Screening is performed in asymptomatic individuals to detect disease early, while diagnostic imaging is ordered when someone has symptoms or signs concerning for cancer. Screening uses lower radiation doses and is focused on early detection in high-risk groups. If you have symptoms such as persistent cough, chest pain, or coughing up blood, you would have a diagnostic CT scan rather than a screening scan.
How often should I get screened?
According to USPSTF guidelines, if you meet eligibility criteria and your screening results are normal (Lung-RADS 1 or 2), you should have annual LDCT screening as long as you continue to meet eligibility criteria. If you're older than 80, have a life expectancy less than 10 years, or no longer meet screening criteria, discuss with your doctor whether continued screening is appropriate.
What if I quit smoking more than 15 years ago?
The USPSTF guidelines recommend screening only for those who quit smoking within the past 15 years. However, your individual risk may be higher or lower depending on other factors such as exposure to radon, secondhand smoke, or occupational carcinogens. Discuss your personal risk with your healthcare provider, as they may recommend screening even if you fall outside the typical guidelines.
Can a normal screening result guarantee I won't get lung cancer?
Unfortunately, no. While LDCT screening is very effective at detecting lung cancer, it's not 100% sensitive. A small percentage of lung cancers may not be visible on screening. Additionally, a cancer could develop between screening exams. For these reasons, it's important to remain aware of symptoms such as a persistent cough lasting more than 2 weeks, chest pain, or shortness of breath, and to report these to your doctor promptly.
Ready to explore clinical trials that may be right for you? Start your search with North's trial finder. Discover innovative screening technologies, early detection trials, and prevention studies that may offer you access to the latest advances in lung cancer research.
References
US Preventive Services Task Force; Krist AH, Davidson KW, Mangione CM, et al. "Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement." JAMA. 2021;325(10):962–970.
National Lung Screening Trial Research Team. "Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening." New England Journal of Medicine. 2011;365(5):395–409.
American Cancer Society. "Can Lung Cancer Be Found Early?" cancer.org.
MacMahon H, Naidich DP, Goo JM, et al. "Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017." Radiology. 2017;284(1):228–243.
Centers for Medicare & Medicaid Services. "CMS Expands Coverage of Lung Cancer Screening with Low Dose Computed Tomography." cms.gov. February 2022.
National Comprehensive Cancer Network. "NCCN Clinical Practice Guidelines in Oncology: Lung Cancer Screening." nccn.org.
